Viva Questions & Answers: Muscle Relaxant Property of Diazepam Using Rota-Rod Apparatus

Section 1: Aim, Principle & Apparatus

• A horizontal rotating rod (~25 mm diameter) driven by an electric motor
• Multiple compartments (usually 4-6) separating individual animals
• An adjustable speed control (typically 5-25 rpm; standard screening speed is 15-18 rpm)
• Individual timers or sensors in each compartment to record fall-off time
• A base platform below the rod to prevent injury to the animals

• A normal, untreated mouse can consistently maintain grip at this speed for at least 3 minutes
• It is sensitive enough to detect drug-induced impairment without being so difficult that control animals fall off spontaneously
• It provides a good signal-to-noise ratio for detecting moderate muscle relaxant activity

Section 2: Drug and Dose

• Dose: 2-5 mg/kg body weight intraperitoneally (i.p.)
• Concentration of stock solution: typically 0.4 mg/ml (so volume administered can be calculated as per body weight)

• I.P. administration gives faster and more reliable absorption than oral in rodents
• It avoids first-pass metabolism, ensuring consistent plasma levels
• Onset of action is quicker (~5-15 min), which is suitable for an acute experiment
• Oral bioavailability in mice is variable

Section 3: Mechanism of Action

1. Binds to a specific benzodiazepine binding site located between the alpha (α) and gamma (γ) subunits of the GABA-A receptor - distinct from the GABA binding site (between α and β subunits) and the barbiturate site
2. This binding increases the frequency of chloride (Cl⁻) ion channel opening (not the duration - that is the barbiturate mechanism)
3. Increased Cl⁻ influx causes hyperpolarization of the neuronal membrane
4. This enhances GABAergic inhibition throughout the CNS, including in the spinal cord interneurons and supraspinal areas, resulting in skeletal muscle relaxation

• Acting on spinal cord interneurons - it enhances GABA-mediated presynaptic inhibition of alpha motor neurons
• Acting supraspinally in the reticular formation and brainstem, reducing descending excitatory drive to the spinal cord
• Reducing polysynaptic reflexes in the spinal cord
• It does NOT act directly on skeletal muscle (unlike dantrolene, which acts at the sarcoplasmic reticulum)

• α1 subunit - mediates sedation, amnesia, and anticonvulsant effects
• α2 and α3 subunits - mediate anxiolysis and muscle relaxation
• This is why non-selective benzodiazepines like diazepam cause both sedation and muscle relaxation

Section 4: Procedure

1. Selection and acclimatization - Select healthy albino mice (20-30 g), acclimatize for 7 days
2. Pre-training (screening) - Place each mouse on the rotating rod (18 rpm) for 3 minutes. Exclude animals that fall off during this pre-screening
3. Baseline recording - Record the fall-off time for each selected mouse (this is the "before drug" time; should be ≥180 seconds for selected mice)
4. Drug administration - Administer diazepam i.p. at the required dose (2-4 mg/kg). Control group receives normal saline (vehicle)
5. Wait - 30 minutes after injection
6. Post-drug observation - Place each mouse again on the Rota-Rod at the same speed and record fall-off time (or confirm whether the mouse can stay on for 3 minutes)
7. Recording - Note body weight, dose, fall-off time before and after drug
8. Calculation - Calculate % decrease in fall-off time or express as % of animals showing muscle relaxant activity

• Group 1 (Control): Normal saline i.p.
• Group 2 (Treatment): Diazepam i.p. at selected dose

Section 5: Results and Inference

• Fall-off time will be significantly reduced compared to baseline and compared to control animals
• Animals may fall off within seconds to a minute (vs. 3 minutes for control mice)
• Higher doses produce a greater reduction in fall-off time (dose-dependent effect)
• The result confirms that diazepam has central muscle relaxant activity

• T₁ = fall-off time before drug (baseline)
• T₂ = fall-off time after drug

Section 6: Pharmacology of Diazepam (Extended Viva)

1. Anxiolytic - reduces anxiety without significant sedation at low doses
2. Sedative-hypnotic - produces dose-dependent CNS depression
3. Anticonvulsant - suppresses seizure activity
4. Skeletal muscle relaxant - via spinal and supraspinal GABA-A enhancement
5. Amnestic - impairs short-term memory (anterograde amnesia)
6. Preanesthetic medication - used for preoperative sedation

• Anxiety disorders
• Alcohol withdrawal syndrome
• Status epilepticus (IV diazepam)
• Skeletal muscle spasm (e.g., tetanus, cerebral palsy, upper motor neuron lesions)
• Preanesthetic medication
• Procedural sedation (e.g., endoscopy, cardioversion)
• Febrile convulsions in children (rectal diazepam)

• Diazepam is highly lipid-soluble, distributing extensively into body fat and brain
• It undergoes hepatic N-demethylation to active metabolite desmethyldiazepam (nordazepam), which itself has a long half-life (36-200 hours) and is further metabolized to oxazepam
• This cascade of active metabolites prolongs the total pharmacological effect

• Sedation and drowsiness (most common)
• Anterograde amnesia
• Respiratory depression (especially with opioids or alcohol - synergism)
• Ataxia and incoordination - directly demonstrable in the rota-rod test
• Paradoxical excitement (especially in elderly and children)
• Physical dependence and withdrawal on long-term use
• Withdrawal features: insomnia, anxiety, tremors, seizures

Section 7: Comparative and Critical Questions

• Central muscle relaxants (e.g., diazepam, baclofen) produce ataxia and impair motor coordination, resulting in early fall-off from the rota-rod
• Peripherally acting relaxants (e.g., dantrolene acts at sarcoplasmic reticulum; neuromuscular blockers act at the NMJ) also reduce grip strength but their profile in the rota-rod differs
• The rota-rod primarily tests neuromuscular coordination, and the fall-off reflects a combination of impaired coordination, sedation, and muscle weakness - making it particularly sensitive for central muscle relaxants

• Mice are easier to train and maintain on the rod due to their lighter weight
• They require smaller doses of drug (cheaper)
• Faster acclimatization
• Cheaper to house; ethical use of fewer animals
• However, rats are sometimes used as well (both species are acceptable)

1. Pre-screen animals and exclude those that cannot complete the baseline trial (unstable animals)
2. Use animals of uniform body weight to ensure consistent dosing
3. Maintain constant rod speed throughout the experiment
4. Perform experiment in quiet, controlled conditions (stress can affect performance)
5. Administer drug by accurate weighing and dosing (mg/kg calculation)
6. Allow adequate time after drug administration before testing (30 min for i.p. diazepam)
7. Use control group (vehicle alone) to rule out handling stress effects
8. Follow CPCSEA/IAEC guidelines for ethical use of laboratory animals

• Cannot distinguish between muscle relaxation and sedation as causes of fall-off; diazepam causes both
• Does not assess peripheral muscle weakness directly
• Inter-animal variability in baseline performance
• Not suitable for testing drugs that cause hyperactivity or tremors (false positives)
• Does not reflect clinical muscle relaxation in humans (translational limitation)

• Regulates animal use in research and education
• Requires IAEC (Institutional Animal Ethics Committee) approval for all animal experiments
• Mandates the 3Rs principle: Replacement, Reduction, Refinement
• Stipulates species-specific guidelines for housing, care, and experimental procedures

• Replacement: Replace animal experiments with alternatives (cell culture, computer models, in vitro methods) wherever possible
• Reduction: Use the minimum number of animals required to get statistically valid results
• Refinement: Modify procedures to minimize pain, distress, and suffering of animals

Section 8: Quick-Fire Short Answers

• Inclined plane test (angle at which animal slides down is recorded)
• Grip strength test (strain gauge measures forelimb grip force)
• Traction test (mouse grips a horizontal wire; muscle relaxant causes inability to hold on)
• Chimney test (mouse cannot climb backwards out of a glass cylinder)

• Katzung's Basic and Clinical Pharmacology, 16th Edition - GABA-A receptor pharmacology, benzodiazepine mechanism
• Goodman & Gilman's The Pharmacological Basis of Therapeutics - Diazepam pharmacokinetics and therapeutic uses
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition - Rota-rod procedure
• Kulkarni SK, Handbook of Experimental Pharmacology - Standard experimental protocols

Viva Questions & Answers: ROTA-ROD APPARATUS

For MD Pharmacology Examination

SECTION 1: Introduction & History

• Neuromuscular coordination
• Vestibular (balance) function
• Grip strength
• Motor planning

SECTION 2: Description of the Apparatus

1. Rotating rod - A horizontal cylinder/rod, approximately 25 mm in diameter, made of metal or hard rubber to provide grip
2. Electric motor - Drives the rod at a controlled, adjustable speed
3. Speed control unit - Allows speed to be set in rpm; typically adjustable from 5 to 25 rpm; the most common fixed speed used is 15-18 rpm
4. Animal compartments - Partitions on the rod divide it into 4-6 lanes, each accommodating one mouse or rat, to prevent animals from interfering with each other
5. Individual timers - One per lane, automatically triggered when the animal falls
6. Padded base / fall platform - Placed below the rod at a height sufficient to motivate the animal to avoid falling, but low enough (usually 30-40 cm) to prevent injury
7. Counter/display - Records time (in seconds) and speed

• Speed: 15-18 rpm (18 rpm is most common for mice)
• Cut-off time: 3-5 minutes (180-300 seconds); animals that remain on for the full cut-off time are considered normal

SECTION 3: Principle

• Impair neuromuscular coordination
• Cause sedation or CNS depression
• Produce skeletal muscle relaxation
• Impair cerebellar or vestibular function

1. Skeletal muscle relaxant activity (primary use)
2. Motor coordination
3. Balance and vestibular function
4. Grip strength
5. Sedation or general CNS depression (as a confound)
6. Fatigue resistance (in accelerating rod models)

SECTION 4: Animal Selection and Pre-screening

• Species: Albino mice or Wistar rats are most commonly used
• Weight of mice: 20-30 g
• Weight of rats: 150-250 g
• Both sexes can be used, but groups must be uniform in sex and weight
• Animals are acclimatized for at least 7 days before the experiment

• Some animals may have inherent deficits in motor coordination unrelated to drugs
• Including such animals in drug-treated groups introduces false positives
• Pre-screening ensures only normally coordinated animals are included
• It also acclimatizes animals to the apparatus, reducing stress-related variability on test day

• They may have pre-existing ataxia, cerebellar abnormalities, or weakness
• Their fall-off time after drug administration would be falsely short, confounding the results
• This upholds the Refinement principle of the 3Rs (reducing suffering and improving data quality)

SECTION 5: Procedure

• Group 1 (Control): Receives vehicle (normal saline, i.p.)
• Group 2 (Standard/Test): Receives diazepam (standard dose: 2-5 mg/kg, i.p.)
• Optional: Multiple dose groups for dose-response

SECTION 6: Results and Inference

• Fall-off time is significantly reduced compared to both the animal's own baseline (T₁) and the control group
• The reduction is dose-dependent: higher doses cause greater reduction
• Some animals may fall off within seconds at higher doses (e.g., 5 mg/kg)
• Control (saline) animals continue to complete the full 3-minute trial

SECTION 7: Applications of the Rota-Rod

1. Screening of centrally acting muscle relaxants - Primary classical use (e.g., benzodiazepines, mephenesin, cyclobenzaprine)
2. CNS depressant/sedative drug evaluation - Ethanol, barbiturates, antihistamines all reduce rota-rod performance
3. Neurotoxicity screening - Detection of motor impairment caused by chemicals, pesticides, heavy metals
4. Evaluation of analgesic side effects - Testing whether analgesics impair motor function
5. Antiepileptic drug research - Rota-rod is used alongside seizure models; drugs that cause ataxia (cerebellar toxicity) will impair performance
6. Traumatic brain injury (TBI) models - Sensitive indicator of motor deficits after experimental TBI in rats
7. Genetic/transgenic animal studies - Testing knockout mice for genes responsible for balance and coordination
8. Disease models - Parkinson's disease, multiple sclerosis, cerebellar ataxia models in rodents
9. Drug interaction studies - Detecting synergistic CNS depression when two drugs are combined

• Primary pharmacological screening - to identify CNS drug activity
• Safety/toxicity screening - to identify motor side effects of candidate drugs before first-in-human trials
• Regulatory guidelines (OECD, ICH S7A) require motor function assessment as part of the CNS safety pharmacology battery

SECTION 8: Drug Classes Studied Using Rota-Rod

• Peripherally acting NMJ blockers (do not cross BBB in standard doses)
• Dantrolene (peripheral mechanism)
• NSAIDs (no CNS motor effects)

SECTION 9: Comparison with Other Motor Function Tests

SECTION 10: Classification of Muscle Relaxants (Extended Viva)

1. GABA-A modulators: Diazepam (benzodiazepines)
2. GABA-B agonists: Baclofen
3. α2-adrenoceptor agonists: Tizanidine, clonidine
4. Mixed CNS depressants: Mephenesin, cyclobenzaprine, methocarbamol, chlorzoxazone, carisoprodol

1. Direct acting (on muscle): Dantrolene - blocks RyR1 channel at sarcoplasmic reticulum
2. Neuromuscular junction blockers (NMJ blockers):
   • Non-depolarizing (competitive): Vecuronium, rocuronium, atracurium
   • Depolarizing: Succinylcholine

SECTION 11: Limitations and Precautions

1. Cannot distinguish sedation from muscle relaxation - A drug causing sedation alone (without true muscle relaxant activity) will also reduce fall-off time, giving false positives for muscle relaxation
2. Learning effect - Animals improve with repeated testing (motor learning), so results from the same animals on different days must account for this
3. Strain differences - Different mouse/rat strains have markedly different baseline rota-rod performance; results are not always transferable
4. Not specific for any one neural pathway - Falls could result from cerebellar, spinal, vestibular, or muscular deficits
5. Translational limitation - Rota-rod performance in rodents does not directly predict the degree of muscle relaxation in humans
6. Confounded by analgesic effects - Some analgesics may alter performance due to impairment in pain-avoidance motivation

1. Pre-screen all animals; exclude non-performers
2. Use animals of uniform weight and age
3. Maintain constant rod speed throughout
4. Conduct experiments in quiet, low-stress conditions
5. Ensure accurate i.p. injection technique (incorrect placement leads to absorption failure)
6. Adhere to the correct pre-treatment time (30 min for diazepam i.p.)
7. Use a vehicle control group always
8. Follow CPCSEA/IAEC guidelines and the 3Rs principle
9. Use a stopwatch or automated sensor for accurate time recording
10. Do not re-test the same animal on the same day (acute drug effects may persist)

SECTION 12: Regulatory and Ethical Aspects

• Obtain approval from the Institutional Animal Ethics Committee (IAEC)
• Submit a protocol describing animal species, number, drug doses, and endpoints
• Justify the number of animals using the 3Rs principle
• Maintain records of all animal use

SECTION 13: Quick-Fire Questions

• Two groups: Student's unpaired t-test
• More than two groups: One-way ANOVA followed by Tukey's or Dunnett's post-hoc test
• Paired data (before/after in same animal): Paired t-test

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition (2011)
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan
• These are the two most cited reference books for preclinical pharmacology practicals in India.

• Katzung's Basic and Clinical Pharmacology, 16th Edition - Dantrolene, benzodiazepine GABA-A pharmacology
• Ganong's Review of Medical Physiology, 26th Edition - Baclofen/GABA-B presynaptic inhibition
• Jones BJ, Roberts DJ (1968). J Pharm Pharmacol, 20:302-304 - Original Rota-Rod description
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed. - Standard lab protocol
• SK Kulkarni, Handbook of Experimental Pharmacology - Standard lab protocol

Viva Questions & Answers: Locomotor Activity Using Actophotometer

CNS Stimulant / Depressant Drug Evaluation in Mice

For MD Pharmacology Examination

SECTION 1: Aim & Introduction

• CNS depressants (e.g., phenobarbitone, diazepam, chlorpromazine, alcohol) reduce spontaneous motor activity by depressing the CNS
• CNS stimulants (e.g., caffeine, amphetamine) increase spontaneous motor activity by activating CNS arousal and motor circuits

SECTION 2: The Actophotometer - Construction and Principle

1. Activity chamber/arena: A square or circular enclosure (typically 30 x 30 cm for mice) with transparent or opaque walls, in which the animal moves freely
2. Photocells (photoelectric cells): Multiple infrared or visible-light sensors arranged along the walls or base of the chamber at regular intervals, at a height corresponding to the animal's body
3. Light source: A beam of light directed at each photocell
4. Electronic counter/digital display: Records each interruption of a light beam as one "count"
5. Timer: Allows activity to be recorded over a set period (typically 5 or 10 minutes)

• A light beam from each light source is continuously directed at its corresponding photocell
• When the animal moves across the chamber, its body interrupts (cuts off) the beam of light falling on the photocell
• Each interruption generates an electrical signal that is recorded as one count on the digital counter
• More movement = more beam interruptions = higher count score
• The total count over a fixed time (e.g., 10 minutes) is the locomotor activity score

SECTION 3: Animals and Requirements

• Species: Albino mice (most common) or Wistar rats
• Weight of mice: 20-25 g (sometimes 20-30 g)
• Animals must be healthy, drug-naive, and acclimatized to the laboratory for at least 7 days before the experiment
• Both sexes can be used but groups must be uniform in sex and weight

• I.P. injection gives rapid and reliable absorption compared to oral administration in rodents
• Avoids first-pass hepatic metabolism (for some drugs)
• Provides consistent onset of action (~10-30 min), allowing a predictable observation window
• Ensures accurate dosing based on body weight

SECTION 4: Procedure

• Group 1 (Control): Normal saline i.p.
• Group 2 (CNS Depressant): Drug (e.g., diazepam 2 mg/kg i.p.)
• Group 3 (CNS Stimulant): Drug (e.g., caffeine 8-10 mg/kg i.p.) (Clean the chamber with 70% ethanol between animals to remove odor cues that affect activity.)

• 1 kg requires 2 mg
• 30 × 10⁻³ kg requires: (2 × 30 × 10⁻³) = 0.06 mg
• Volume to inject: 0.06 mg ÷ 0.2 mg/mL = 0.3 mL

SECTION 5: Results and Inference

• Post-drug score (S₂) is significantly lower than pre-drug baseline (S₁)
• % decrease is typically 55-80% at therapeutic doses
• Control (saline) animals show no significant change in activity score
• Conclusion: Reduction in locomotor activity indicates CNS depressant property of the drug

• Post-drug score (S₂) is significantly higher than pre-drug baseline (S₁)
• Animals show hyperactivity, increased exploration, and sometimes stereotypic movements
• Conclusion: Increase in locomotor activity indicates CNS stimulant property of the drug

SECTION 6: Mechanism of Action of Drugs Used

• Sedation and decreased arousal
• Reduced spontaneous locomotor activity
• Anxiolysis, muscle relaxation, and anticonvulsant effects

• Neurolepsis - a state of extreme reduction in spontaneous motor activity and behavioral indifference in animals
• Sedation (also via H1 and α1 blockade)
• Psychomotor slowing

• Binds to a specific barbiturate site on the GABA-A receptor (distinct from the benzodiazepine site)
• Increases the duration of chloride ion channel opening (unlike benzodiazepines which increase frequency)
• At higher concentrations, can directly activate GABA-A receptors even without GABA (no ceiling effect - hence narrower safety margin than benzodiazepines)
• Also inhibits AMPA/kainate glutamate receptors
• Net effect: widespread CNS depression, reduced arousal, reduced locomotor activity

• Acts as a neuromodulator that reduces spontaneous neuronal activity and promotes sleep
• A1 receptors: inhibit neuronal firing
• A2A receptors: inhibit dopaminergic activity in the striatum

• Removing adenosine's inhibitory brake on neuronal activity
• Increasing dopamine signaling in the nucleus accumbens (via blockade of A2A-D2 receptor heteromers), which drives locomotion
• Increasing arousal via the ascending reticular activating system
• Resulting in increased spontaneous locomotor activity, wakefulness, and motor hyperactivity

1. Enters presynaptic terminals via monoamine transporters (DAT, NET)
2. Displaces dopamine and norepinephrine from storage vesicles (cytoplasmic pool) into the cytoplasm
3. Reverses the direction of DAT and NET transporters (carrier-mediated reverse transport), causing massive outflow of dopamine and norepinephrine into the synapse
4. Inhibits monoamine oxidase (MAO), reducing catecholamine breakdown

SECTION 7: Classification of CNS Stimulants and Depressants

1. Methylxanthines: Caffeine, theophylline, theobromine
2. Sympathomimetics / Indirect catecholamine agonists: Amphetamine, methamphetamine, methylphenidate
3. Cocaine: Blocks reuptake of dopamine, norepinephrine, serotonin

1. GABA antagonists: Picrotoxin (blocks Cl⁻ channel), bicuculline (GABA-A antagonist)
2. Glycine antagonists: Strychnine (spinal cord)
3. Phosphodiesterase inhibitors: Theophylline at high doses

1. Inhalation anesthetics: Ether, halothane
2. General anesthetics: Ketamine, propofol
3. Alcohol (ethanol)

1. Benzodiazepines: Diazepam, lorazepam, midazolam
2. Barbiturates: Phenobarbitone, thiopentone
3. Non-BZD hypnotics: Zolpidem, zaleplon

• Chlorpromazine, haloperidol, olanzapine

• Morphine, codeine (reduce locomotion at high doses)

• Promethazine, diphenhydramine

SECTION 8: Comparison with Other Instruments

• The actophotometer gives a single count score (total horizontal movement) with no spatial information; it is primarily used for gross locomotor activity to classify CNS effects
• The open field test records locomotion in different zones of the arena and also measures rearing, grooming, defecation, and center-zone exploration - giving a more detailed behavioral profile including anxiety
• Open field test requires video tracking software; actophotometer is simpler and requires only a photocell counter

SECTION 9: Applications of the Actophotometer

1. CNS drug classification - Primary use: distinguish CNS stimulants from depressants
2. Screening of new psychotropic drugs - During preclinical drug development
3. Evaluation of sedative-hypnotic drugs - Barbiturates, benzodiazepines, antihistamines
4. Evaluation of antipsychotic drugs - Detect neuroleptic (D2 blocking) activity
5. Toxicity screening - Detect CNS effects of toxic substances, plant extracts, herbal drugs
6. Drug interaction studies - Test whether two drugs potentiate or antagonize each other's CNS effects
7. Ethanol studies - Dose-dependent CNS depressant effect of alcohol
8. Neurotoxicology - Assess motor effects of environmental toxins, pesticides
9. Circadian rhythm research - Measure diurnal variation in spontaneous activity

SECTION 10: Precautions, Limitations, and Ethical Aspects

1. Check all photocells before the experiment - a malfunctioning cell gives falsely low counts
2. Clean the chamber between animals with 70% ethanol - residual odors from previous animals (especially urine) increase/decrease exploration behavior in the next animal (olfactory stimulation effect)
3. Conduct the experiment at the same time of day - locomotor activity is highest during the dark (active) phase in nocturnal rodents; circadian variation introduces significant confounding
4. Use animals of uniform body weight and sex - heavier animals may move less in a confined space
5. Ensure the testing room is quiet and dark (or consistently lit) - noise and light startle responses affect activity
6. Acclimatize each animal individually in the room for at least 1 hour before testing
7. Use an adequate control group (vehicle/saline)
8. Administer drugs at the correct pre-treatment time (30 min for i.p. administration)
9. Record activity for a fixed duration (10 minutes) consistently across all animals
10. Follow CPCSEA / IAEC guidelines for ethical animal use

1. Non-specific endpoint: Cannot distinguish between reduced locomotion due to true CNS depression vs. muscle weakness vs. ataxia vs. pain
2. Confounded by novelty response: On first placement in the chamber, animals show exploratory activity (novelty-induced activity). This habituates over time, so results depend on whether baseline includes novelty effects
3. Does not capture behavioral quality: Only counts beam interruptions - cannot tell if animal is rearing, grooming, freezing, or making stereotypic movements
4. Circadian sensitivity: Nocturnal animals (mice) have markedly higher activity at night; time-of-day confound is significant
5. No spatial information: Cannot tell which part of the arena the animal is in (center vs. periphery), so cannot assess anxiety simultaneously
6. Olfactory priming: Odors left by previous animals can alter the activity of subsequent animals unless cleaned thoroughly
7. Inter-animal variability: Individual mice have widely varying baseline activity scores, requiring adequate sample sizes

SECTION 11: Quick-Fire Questions

• Benzodiazepines: Increase frequency of Cl⁻ channel opening (require GABA to be present; positive allosteric modulator)
• Barbiturates: Increase duration of Cl⁻ channel opening; at high concentrations can open channels even without GABA - this explains why barbiturates have no ceiling effect and are more dangerous in overdose

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition - Standard Indian pharmacology practical text
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Caffeine mechanism (adenosine A1/A2A antagonism)
• Stahl's Essential Psychopharmacology, 5th Edition - Chlorpromazine, D2 receptor, neurolepsis
• Katzung's Basic and Clinical Pharmacology, 16th Edition - Benzodiazepine vs. barbiturate GABA-A mechanisms
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed - Standard actophotometer protocol
• SK Kulkarni, Handbook of Experimental Pharmacology - Standard actophotometer protocol

Viva Questions & Answers: ACTOPHOTOMETER

For MD Pharmacology Examination

SECTION 1: Introduction & Definition

• Pharmacological classification of drugs as CNS stimulants or depressants
• Quantification of the degree of CNS effect
• Preclinical safety screening - detecting unwanted motor side effects of new drug candidates
• Drug interaction assessment - potentiation or antagonism of CNS effects

SECTION 2: Principle

• Multiple infrared (IR) light beams are projected horizontally across the interior of the activity cage from light-emitting sources on one wall to photoelectric sensors on the opposite wall
• Under resting conditions, each light beam continuously strikes its corresponding photosensor - no count is generated
• When an animal moves inside the cage, its body physically interrupts (breaks) a light beam, preventing it from reaching the photosensor
• The photosensor detects this interruption and converts it into an electrical signal
• Each signal is registered as one count on a digital counter
• The total count accumulated over a fixed observation period (typically 10 minutes) = the animal's locomotor activity score

• Incident light generates a small electric current
• When the light beam is blocked, the current drops to zero
• This on/off change in current is detected by the circuit and counted electronically

SECTION 3: Construction and Components

A. Activity Cage (Chamber)

1. Enclosure/Arena: A square (typically 30 × 30 cm for mice) or circular transparent acrylic or metal chamber with solid walls, open top or mesh top for ventilation
2. Grid floor: Allows feces and urine to drop through, keeping the chamber clean
3. Tray: Below the grid to collect waste
4. Dimensions: Designed to be large enough for free movement but small enough to ensure all movements cross beams (typically 25-30 cm × 25-30 cm × 25 cm height for mice)

B. Sensor System

1. Infrared (IR) light sources: Multiple IR LED emitters placed at regular intervals along one or two walls of the cage, at a height corresponding to the animal's mid-body (~3-5 cm from the floor for mice)
2. Photoelectric sensors (photocells): Corresponding IR photodetectors placed directly opposite each emitter on the other wall, receiving the continuous beam when uninterrupted
3. Number of beams: Typically 4-16 beams depending on the model; more beams = better resolution

C. Control Panel / Electronics

1. Power switch and indicator: Turns the instrument on/off
2. Digital counter (4-digit display): Counts and displays each beam interruption as a numerical count; shows the running total
3. Timer: Built-in timer to set the observation duration (5 or 10 minutes)
4. Reset button: Resets the counter to zero before each animal is tested
5. Electric shock provision (in some models): A shock button/meter for testing drug-induced hyper- or hypo-sensitivity (not used in standard locomotor activity testing)
6. Sensitivity adjustment: Allows calibration to prevent false counts from vibration

• Square chamber is more common - easier to position photocells along straight walls; cleaner beam geometry
• Circular chamber - used when spatial mapping of locomotion is less important; avoids corner-sitting behavior (animals tend to spend time in corners of square cages, which can reduce beam interruptions and underestimate activity)

SECTION 4: Types of Actophotometers

• Spontaneous locomotor activity: The natural, undisturbed movement of the animal when placed in a novel environment, driven by exploratory behavior. This is what the actophotometer primarily measures
• Induced locomotor activity: Activity deliberately provoked by a stimulus (e.g., electric shock, forced movement)

SECTION 5: Measurement Parameters

1. Spontaneous locomotor activity (primary parameter) - total horizontal movement score
2. Exploratory behavior - initial burst of activity in a novel environment (novelty-induced locomotion)
3. Resting behavior - periods of inactivity (low or zero counts)
4. Stereotypic behavior - repetitive, limited movement patterns (e.g., head bobbing in one spot; may give falsely elevated counts)
5. Anxiety and fear response - fearful animals "freeze" and show very low counts (thigmotaxis - staying near walls)
6. Habituation - progressive decrease in activity over time as novelty wears off
7. Drug-induced hyperactivity or hypoactivity - compared to baseline/control

SECTION 6: Calibration

1. Switch on the instrument and allow it to warm up for 5-10 minutes
2. Ensure the counter reads zero with no animal inside; adjust baseline if needed
3. Check that all photocells are functioning: manually pass an object (e.g., a pen) through each beam one at a time and verify that each pass registers exactly one count
4. If any photocell is not registering, clean the sensor surface; replace if faulty
5. Test with a mock object moving through the chamber at a known number of crossings to verify count accuracy
6. Clean the chamber with 70% ethanol, allow to dry completely (ethanol odor must clear before placing animals)
7. Set the timer to the required observation period (10 minutes)
8. Ensure ambient lighting and noise are at the standard level

SECTION 7: Animals Used

• Healthy, drug-naive
• Uniform body weight (within ±20% of group mean)
• Acclimatized for 7 days in laboratory conditions
• Same sex within each group
• No visible signs of injury, illness, or behavioral abnormality

• Smaller size → less drug required → cheaper
• More active explorers → higher baseline locomotor activity counts → larger dynamic range for detecting drug-induced changes
• Easier to handle and dose accurately
• Lower ethical concern (less sentient per CPCSEA guidelines per unit number)
• Faster breeding → easier to maintain colony

SECTION 8: Procedure Summary

1. Acclimatize animals (7 days standard housing; 1 hour in test room before experiment)
2. Weigh and number each animal
3. Switch on and calibrate the actophotometer; verify all photocells working
4. Place each animal individually in the chamber for 10 minutes - record baseline (pre-drug) count (Score S₁)
5. Clean chamber with 70% ethanol between animals; allow to dry
6. Administer test drug or vehicle i.p. at calculated dose based on body weight
7. Wait 30 minutes (pre-treatment time for i.p. drugs)
8. Place each animal again in the chamber for 10 minutes - record post-drug count (Score S₂)
9. Calculate % change in locomotor activity

• The smell of another animal's urine can increase exploratory/investigatory behavior (false elevation)
• Alternatively, stress pheromones can cause freezing behavior (false reduction)
• Cleaning with 70% ethanol removes olfactory cues and ensures each animal starts on a neutral environment

• 10 minutes is long enough to capture a representative sample of activity including initial novelty-driven exploration and early habituation
• Short enough that the animal does not become exhausted or overly habituated
• Standard across most published protocols (some use 5 minutes for faster assays)
• Allows statistical comparability across studies

SECTION 9: Interpretation of Results

• Two groups (drug vs. control): Student's unpaired t-test
• Multiple groups: One-way ANOVA followed by Tukey's or Dunnett's post-hoc test
• Paired data (same animal before and after): Paired t-test
• p < 0.05 is taken as statistically significant

SECTION 10: Drugs Tested - Standard Doses

SECTION 11: Neuropharmacological Basis

1. Dopaminergic system: The mesolimbic (VTA → nucleus accumbens) and nigrostriatal (substantia nigra → striatum) dopamine pathways are the primary regulators of locomotion. Dopamine in the striatum/nucleus accumbens drives exploratory and goal-directed locomotion. This is why dopamine-blocking drugs (antipsychotics) reduce locomotion and dopamine-releasing drugs (amphetamine) increase it.
2. Ascending Reticular Activating System (ARAS): The ARAS maintains wakefulness and arousal via five neurotransmitters - histamine, dopamine, norepinephrine, acetylcholine, and serotonin - and orexins. CNS depressants suppress the ARAS, reducing arousal and locomotion. CNS stimulants activate it. (Source: Stahl's Essential Psychopharmacology)
3. GABAergic system: Increased GABAergic tone (via benzodiazepines, barbiturates) inhibits all CNS circuits including motor control, reducing locomotion
4. Adenosine system: Adenosine suppresses CNS activity; caffeine blocks adenosine receptors (A1, A2A) and removes this inhibitory tone, increasing locomotion
5. Noradrenergic system: Norepinephrine from the locus coeruleus maintains arousal; drugs enhancing NE (amphetamine, atomoxetine) can increase activity

SECTION 12: Applications

1. CNS drug classification - Identifying whether a new drug or herbal extract is a CNS stimulant or depressant
2. Sedative-hypnotic drug evaluation - Quantifying the degree of sedation (benzodiazepines, barbiturates, antihistamines, opioids)
3. Antipsychotic drug screening - Detecting neuroleptic (D2-blocking) activity via reduction in locomotion
4. Anxiolytic drug screening - Reduced locomotion may reflect either sedation or anxiolytic activity (needs to be distinguished from EPM or open field tests)
5. CNS stimulant identification - Caffeine, amphetamine, methylphenidate, modafinil screening
6. Neurotoxicity assessment - Detecting CNS motor impairment caused by toxins, pesticides, heavy metals
7. Herbal/plant extract pharmacology - Preliminary CNS activity screening of phytochemicals
8. Drug interaction studies - Detecting potentiation (synergism) or antagonism of CNS effects when two drugs are given together
9. Circadian pharmacology - Studying diurnal variation in drug response
10. Substance abuse research - Measuring ethanol-induced, cocaine-induced, or amphetamine-induced hyperactivity
11. Tolerance and dependence studies - Measuring changes in locomotor response on repeated drug administration
12. Behavioral sensitization - Repeated amphetamine administration produces progressive increase in locomotor response (sensitization); measured by actophotometer

SECTION 13: Comparison with Related Instruments

SECTION 14: Precautions and Limitations

1. Calibrate before every experiment - check all photocells are functional
2. Clean the chamber between animals with 70% ethanol; allow to dry fully
3. Test one animal at a time - never place two animals simultaneously
4. Maintain consistent lighting and noise - testing room must be quiet and uniformly lit
5. Conduct experiments at the same time of day - mice are nocturnal; activity peaks in the dark phase
6. Gentle handling - rough handling causes stress-induced changes in locomotion
7. Acclimatize animals to the testing room for at least 1 hour before testing
8. Use freshly prepared drug solutions - degraded solutions give unreliable results
9. Ensure correct pre-treatment time - testing too early or too late gives inaccurate results
10. Do not place equipment near vibrating machinery - vibrations trigger false counts
11. Follow CPCSEA / IAEC guidelines for all animal procedures

1. Non-specificity: Cannot distinguish between reduced activity due to sedation, muscle weakness, pain, ataxia, or fear - all give the same outcome (lower count)
2. Novelty confound: The animal's initial exploratory burst (due to novel environment) is included in the pre-drug baseline, making the baseline artificially high; habituation occurs over repeated testing
3. Stereotypy problem: A drug causing repetitive stereotypic movements in a small area may generate high counts without true "locomotion" (e.g., apomorphine-induced stereotypy)
4. No spatial information: Cannot tell where in the cage the animal is or what behavior it is performing
5. Circadian variation: Results vary significantly with time of day; nocturnal peak activity in mice means experiments done at different times give inconsistent results
6. Olfactory interference: Unless cleaned thoroughly between animals, olfactory cues alter the next animal's activity
7. No behavioral quality: Does not distinguish purposeful exploration from random movement or freezing interspersed with bursts

SECTION 15: Quick-Fire Questions

• CNS Stimulant: Caffeine 8-10 mg/kg i.p. in mice
• CNS Depressant: Diazepam 2 mg/kg i.p. in mice

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan

• Stahl's Essential Psychopharmacology, 5th Edition - ARAS neurobiology; dopamine and locomotion
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Caffeine/adenosine pharmacology
• IJPS Journal - "Instrumental Approaches in Neuropharmacological Screening" - Actophotometer review
• King George's Medical University (KGMU), Lucknow - Actophotometer Standard Operating Procedure
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed
• SK Kulkarni, Handbook of Experimental Pharmacology

Viva Questions & Answers: Anticonvulsant Activity of Phenytoin Against MES-Induced Convulsions Using Electroconvulsiometer

For MD Pharmacology Examination

SECTION 1: Aim, Introduction & Definitions

• A seizure is a single episode of abnormal, excessive neuronal discharge that manifests as transient changes in behavior, consciousness, sensation, or motor function
• Epilepsy requires at least two unprovoked seizures separated by >24 hours, or one unprovoked seizure with a high likelihood of recurrence (>60%)
• A seizure can occur in normal brains under extreme provocation (e.g., high fever, electrolyte imbalance, drugs) - this is not epilepsy unless seizures recur spontaneously

1. Paroxysmal depolarization shift (PDS): A sudden, large depolarization of a neuron persists due to excessive sodium and calcium influx
2. Normally, inhibitory interneurons suppress this; in epilepsy this inhibition fails
3. The abnormal discharge spreads to neighboring neurons via gap junctions, excitatory synapses, and extracellular potassium accumulation
4. Synchronous firing of large neuronal populations produces the clinical seizure
5. The MES model replicates this by delivering supramaximal current that overwhelms normal inhibitory mechanisms

SECTION 2: Classification of Seizures and Epilepsy

• Simple focal (no loss of consciousness) - psychomotor seizures
• Complex focal (with impaired consciousness)
• Focal evolving to bilateral tonic-clonic

1. Tonic-clonic (Grand Mal) - tonic stiffening + clonic jerking; loss of consciousness; modeled by MES test
2. Absence (Petit Mal) - brief lapses of consciousness; modeled by Pentylenetetrazol (PTZ) test
3. Myoclonic
4. Atonic (drop attacks)
5. Tonic
6. Clonic

SECTION 3: The Electroconvulsiometer - Instrument

A. Power and Control Unit

1. AC power supply: The instrument generates alternating current (AC) at defined parameters
2. Current intensity control: Adjustable current output, typically 10-150 mA; standard for mice is 25-50 mA (supramaximal intensity)
3. Frequency control: Typically 50-60 Hz (standard mains AC frequency)
4. Duration/pulse width timer: Controls how long the current is delivered; standard duration is 0.2-0.8 seconds (200-800 milliseconds)
5. Voltage/current meter: Displays the actual current being delivered
6. ON/OFF switch and indicator light

B. Electrode System (two types used alternately)

1. Corneal electrodes: Small cup-shaped silver/stainless steel electrodes applied directly to the cornea of both eyes; a drop of saline or electrolyte gel is applied first to reduce resistance. Most reliable for mice.
2. Ear-clip (pinna) electrodes: Metal clips applied to the ears. Used in rats more often.

C. Additional Features

1. Foot platform / animal holder: Platform on which the animal stands during stimulation
2. Pulse/shock button: Triggers the current delivery

• It produces bidirectional membrane depolarization - more effective at triggering neuronal firing
• It is more reliable in producing consistent, reproducible maximal seizures
• It more closely mimics the synchronous bilateral neural discharge pattern of a generalized seizure
• DC would cause electrolytic tissue damage at the electrode sites

• Every control animal convulses, providing a clear baseline
• Results are reproducible and comparable across laboratories
• Drugs that partially elevate seizure threshold are still detectable
• It simulates the "maximal" spread of epileptic discharge seen in severe generalized epilepsy

SECTION 4: Principle of the MES Model

1. Widespread depolarization of neuronal membranes throughout the brain
2. Synchronous firing of billions of neurons simultaneously
3. A characteristic generalized tonic-clonic convulsion - the Maximal Electroshock Seizure (MES)

SECTION 5: Phases of MES Convulsion

• It represents maximal seizure spread across the whole brain
• It is all-or-none: either complete THLE is present (≥180°) or it is absent
• It is the phase most reliably abolished by anticonvulsant drugs effective against generalized tonic-clonic epilepsy
• It is easy to observe and score (present/absent)
• The endpoint in the experiment is typically: "abolition of THLE" after phenytoin treatment

SECTION 6: Procedure

• Group 1 (Control): Receives vehicle (normal saline or 0.5% CMC, i.p.)
• Group 2 (Treatment): Receives phenytoin sodium (standard dose: 25-30 mg/kg, i.p. or p.o.)
• Each group: minimum 6 animals

• Inject phenytoin sodium (25-30 mg/kg i.p.) or vehicle
• Wait 30-60 minutes for the drug to reach peak plasma levels

• Apply a drop of normal saline or electrolyte gel to both corneas of the mouse
• Place corneal electrodes gently on both corneas

• Set the electroconvulsiometer to the standard parameters: 50 mA, 50 Hz, 0.2 seconds
• Press the shock button to deliver the current
• Immediately hold the mouse by the scruff of the neck in a flat position to allow proper observation of hind-limb posture

• Observe and record all phases: tonic flexion, THLE (present/absent and angle), clonic convulsions, stupor, recovery
• Primary endpoint: Presence or absence of THLE
• Note duration of each phase

• Control (saline): 0% protection (100% show THLE)
• Phenytoin-treated: Expected 80-100% protection at 25-30 mg/kg

SECTION 7: Mechanism of Action of Phenytoin

1. Voltage-gated Na⁺ channels exist in three states:
   • Resting (closed) - ready to open
   • Active (open) - allowing Na⁺ influx during action potential
   • Inactivated (closed but refractory) - immediately after the action potential
2. Phenytoin binds selectively to the inactivated state of the Na⁺ channel and stabilizes it in this non-conducting inactivated state (membrane stabilization)
3. This prolongs the refractory period of the channel - the channel takes longer to return to the resting state, limiting the ability of the neuron to fire at high frequencies
4. Use-dependence: The more frequently a neuron fires (as in epilepsy), the more channels enter the inactivated state and the stronger phenytoin's blocking effect. Normal, low-frequency neuronal firing is much less affected.
5. Net result: Selectively suppresses high-frequency repetitive neuronal firing without significantly affecting normal neuronal activity. This prevents the spread of epileptic discharge.
6. Additional mechanism: Phenytoin also reduces calcium entry through voltage-gated Ca²⁺ channels at nerve terminals, reducing neurotransmitter release.

• Generalized tonic-clonic (Grand Mal) seizures - first-line use (detected by MES model)
• Focal (partial) seizures - simple and complex partial
• Status epilepticus (IV phenytoin or fosphenytoin)
• Trigeminal neuralgia (membrane stabilization)
• Cardiac arrhythmias (Class Ib antiarrhythmic - digitalis-induced arrhythmia)

• Absence (Petit Mal) seizures - may worsen them
• Myoclonic seizures
• Atonic seizures

SECTION 8: Pharmacokinetics of Phenytoin

• At low plasma concentrations: phenytoin follows first-order kinetics - a constant fraction of the drug is eliminated per unit time; half-life is ~12-24 hours
• At therapeutic plasma concentrations (~10-20 mcg/mL): the hepatic hydroxylation enzymes (CYP2C9) become saturated
• Once saturated, elimination switches to zero-order kinetics - a fixed amount (not fraction) of drug is eliminated per unit time regardless of concentration
• This means: a small increase in dose causes a disproportionately large increase in plasma concentration (non-linear pharmacokinetics)
• Clinically dangerous: minor dose increases can suddenly push levels into the toxic range (>20 mcg/mL)
• This is why phenytoin requires therapeutic drug monitoring (TDM)

• Therapeutic range: 10-20 mcg/mL (40-80 µmol/L)
• Below 10 mcg/mL: likely sub-therapeutic
• 20-30 mcg/mL: nystagmus (earliest sign of toxicity)
• 30-40 mcg/mL: ataxia, diplopia, mental confusion

• 40 mcg/mL: severe CNS depression, coma

SECTION 9: Adverse Effects of Phenytoin

• Nystagmus (first sign - at ~20 mcg/mL)
• Diplopia and blurred vision
• Ataxia (>30 mcg/mL)
• Mental confusion, sedation
• Coma (>40 mcg/mL)
• The mnemonic is: N-D-A-C (Nystagmus → Diplopia → Ataxia → Confusion/Coma)

• Gingival hyperplasia (gum overgrowth) - most characteristic; occurs in ~50% of patients; due to altered collagen metabolism; can be reduced by good oral hygiene
• Hirsutism (facial hair growth, especially in females)
• Coarsening of facial features
• Peripheral neuropathy (with chronic use)
• Osteomalacia (induction of CYP enzymes → increased vitamin D metabolism → reduced calcium absorption)
• Megaloblastic anemia (folate deficiency - phenytoin interferes with folate absorption)
• Lymphadenopathy (sometimes mimics lymphoma)

• Steven-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) - rare but life-threatening
• Hypersensitivity reactions - fever, rash, hepatitis ("anticonvulsant hypersensitivity syndrome")
• Drug-induced lupus (rare)

• Fetal Hydantoin Syndrome: cleft palate/lip, cardiac defects, digital hypoplasia, fetal growth restriction; Category D drug in pregnancy

• Hypotension and bradycardia (due to propylene glycol vehicle) - must not be given faster than 50 mg/min
• Purple Glove Syndrome: local tissue necrosis/discoloration at IV site
• Cardiac arrhythmias at rapid infusion rates (Fosphenytoin - water-soluble prodrug - is safer for IV use)

SECTION 10: Drug Interactions

• Isoniazid (INH) - inhibits CYP2C9 (important: TB-epilepsy co-treatment)
• Cimetidine - CYP2C9 inhibitor
• Fluconazole - CYP2C9 inhibitor
• Amiodarone, fluvoxamine
• Valproate - displaces phenytoin from protein binding (increases free fraction)

• Carbamazepine - CYP inducer
• Rifampicin - potent CYP inducer

• Oral contraceptives - reduced efficacy (contraceptive failure)
• Warfarin - initially increases, then decreases anticoagulant effect
• Corticosteroids, cyclosporin - reduced levels
• Antifungals (azoles) - reduced efficacy
• Other AEDs - carbamazepine, lamotrigine levels reduced

SECTION 11: Classification of Antiepileptic Drugs

• Phenytoin, Carbamazepine, Oxcarbazepine, Lamotrigine, Lacosamide, Eslicarbazepine

• Ethosuximide, Valproate (partly)

• Benzodiazepines (diazepam, clonazepam, lorazepam)
• Barbiturates (phenobarbitone)
• Tiagabine (GABA reuptake inhibitor)
• Vigabatrin (GABA transaminase inhibitor)

• Baclofen (not primary AED but used in spasticity)

• Felbamate (NMDA antagonist + Na⁺ channel blocker)
• Perampanel (AMPA antagonist)

• Valproate: Na⁺ channel block + T-Ca²⁺ block + GABA enhancement + reduces GABA transaminase; broadest spectrum AED
• Levetiracetam: Binds SV2A (synaptic vesicle protein 2A) - unique mechanism; broad spectrum
• Gabapentin/Pregabalin: Bind α2δ subunit of voltage-gated Ca²⁺ channels

SECTION 12: Comparison of Anticonvulsants

SECTION 13: Precautions and Ethical Aspects

1. Use supramaximal current to ensure 100% seizure in all control animals; verify by testing control group first
2. Apply saline or electrolyte gel to the cornea before placing electrodes - reduces resistance and prevents corneal burns
3. Hold the mouse by the scruff immediately after shock to prevent injury from falling during THLE
4. Allow animals to fully recover between repeated shocks; do not re-shock immediately
5. Use adequate sample size (minimum n=6 per group) for statistical validity
6. Administer drug at the correct pre-treatment time (30 min for i.p. phenytoin)
7. Use identical current parameters across all animals - calibrate electroconvulsiometer before each session
8. Follow CPCSEA/IAEC guidelines; obtain IAEC approval
9. Keep the testing environment quiet to avoid additional sensory stimuli confounding results
10. The experiment should be performed by trained personnel - electrical stimulation can cause animal fatalities at excessive parameters

• Replacement: Use in vitro Na⁺ channel binding assays, computational modeling, or patch-clamp electrophysiology as primary screens; use MES only for confirmatory in vivo testing
• Reduction: Calculate minimum sample size (n=6-8 by power analysis); use within-subject designs where possible
• Refinement: Use precise current parameters to avoid unnecessary severity; apply analgesia if appropriate; provide proper post-procedure care

SECTION 14: Quick-Fire Questions

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan

• IJPS Journal: "Instrumental Approaches in Neuropharmacological Screening" - Electroconvulsiometer and MES model
• Melior Discovery: MES model phenytoin dose-response data
• Katzung's Basic and Clinical Pharmacology, 16th Edition - Antiepileptic pharmacology
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Phenytoin mechanism and kinetics
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed - Standard MES protocol

Viva Questions & Answers: ELECTROCONVULSIOMETER

For MD Pharmacology Examination

SECTION 1: Introduction & Definition

• Screen new compounds for anticonvulsant activity
• Evaluate the efficacy of known antiepileptic drugs
• Study the neurobiological basis of epilepsy
• Characterize different phases of electrically induced convulsions

• Inexpensive, simple, and reproducible
• Requires no specialized housing or chemical reagents (unlike chemical convulsants)
• Produces 100% seizure rate in control animals - ideal for anticonvulsant screening
• Endorsed by regulatory bodies (OECD, NINDS) as a standard preclinical tool

SECTION 2: Principle

1. When a supramaximal alternating current of defined parameters (intensity, frequency, duration) is delivered to the brain through corneal or ear-clip electrodes, it causes widespread, simultaneous depolarization of neuronal membranes throughout the brain
2. This overcomes the normal inhibitory restraints and produces synchronous firing of vast populations of neurons
3. The result is a generalized tonic-clonic convulsion - specifically the Maximal Electroshock Seizure (MES) - that mimics human Grand Mal epilepsy
4. The most characteristic phase is Tonic Hind-Limb Extension (THLE) - hindlimbs extend rigidly at ≥180° to the body axis
5. An anticonvulsant drug pre-administered to the animal abolishes or reduces the THLE phase by preventing maximal seizure spread
6. Abolition of THLE = anticonvulsant protection - this is the primary endpoint

• AC produces bidirectional membrane depolarization at both electrodes simultaneously - more effective at triggering synchronous neuronal firing than DC
• AC causes less electrolytic tissue damage at electrode sites (DC would cause oxidation/reduction reactions damaging the cornea and brain)
• AC is more reproducible and produces consistent, maximal convulsions at lower intensity than DC
• AC closely mimics the bidirectional ionic fluctuations seen in natural seizure discharges
• Mains AC frequency (50-60 Hz) is the international standard for MES models

SECTION 3: Construction and Components

A. Stimulus Generator Unit

1. Stimulus generator (primary unit): Produces the electrical stimulus with precisely controlled parameters
   • Generates square wave AC pulses (square waves are more effective in eliciting maximal seizures than sinusoidal waves because they produce rapid, uniform membrane depolarization)
   • Adjustable parameters: current intensity (50-150 mA), frequency (50-60 Hz), duration (0.2-0.5 seconds)
2. Current intensity control dial/knob: Sets the output current in milliamperes (mA)
   • Mice: 50 mA (supramaximal)
   • Rats: 150 mA (supramaximal)
3. Frequency selector: Sets Hz; standard 50-60 Hz (mains frequency)
4. Duration/Timer control: Sets how long the shock lasts; standard 0.2 seconds (200 ms)
5. Current/Voltage meter (ammeter/voltmeter): Displays the actual current delivered to the animal, allowing verification that the set current was actually delivered
6. Power ON/OFF switch with indicator light
7. Shock/Trigger button: Momentary push-button that delivers the current; some models have a foot-pedal trigger for hands-free operation

B. Electrode System

1. Corneal electrodes (primary for mice): Small cup/disc-shaped silver or stainless steel electrodes placed directly on each cornea; most reliable; NINDS standard for mice
2. Ear-clip (pinna) electrodes (primary for rats): Metal spring-clips applied to the pinnae; simpler to apply; some protocols use ear-clips for both species
3. Electrode leads/cables: Connect the electrodes to the control unit; color-coded (usually red and black for positive/negative poles, though AC does not have fixed polarity)

C. Animal Platform

1. Holding platform/table: Where the animal stands during stimulation; grounded metal platform in some designs
2. Restraint guide (optional): Helps position the animal consistently before electrode application

• Square waves have a near-instantaneous rise time and maintain constant amplitude throughout each pulse - they depolarize the neuronal membrane rapidly and completely with each cycle
• Sinusoidal waves gradually rise and fall - the membrane may partially repolarize during the gradual phase transitions, requiring higher total current to achieve maximal effect
• Square waves produce more consistent, reproducible maximal seizures at lower current intensities, reducing unnecessary tissue stress
• They are the current standard for all NINDS-approved MES protocols

SECTION 4: Electrode Types and Their Use

1. Reduce electrical resistance at the electrode-cornea interface - saline (electrolyte solution) dramatically improves electrical conductivity compared to dry corneal epithelium, ensuring the set current is actually delivered to the brain
2. Prevent corneal burns/drying - dry cornea under a metal electrode with current passing through it can suffer electrothermal injury
3. Ensure reproducible current delivery - wet contacts have consistent, low-impedance coupling

SECTION 5: Electrical Parameters

• Supramaximal current: A current above the threshold needed to produce maximal convulsions in 100% of untreated animals. This ensures:
  • All control animals show a complete, standardized convulsion
  • The THLE phase is always present in controls - provides a clear positive control
  • Drug effects can be detected even if the drug only partially raises the seizure threshold
  • Results are reproducible across laboratories
• Subthreshold current: Would produce inconsistent, partial, or no convulsions in some control animals - this makes it impossible to distinguish drug-induced protection from naturally occurring non-convulsion

• Seizure threshold: The minimum current intensity required to produce any seizure activity in an animal
• Maximal seizure (MES): A supramaximal stimulus that produces the complete, characteristic tonic-clonic convulsion pattern including THLE in all animals - no sub-maximal or partial convulsions

1. Raise the seizure threshold (tested by finding the minimum current needed to produce a seizure after drug vs. control) - ETZ (Electroshock Threshold Test)
2. Prevent maximal seizure spread (tested by MES at fixed supramaximal current) - MES Test

SECTION 6: Tests Performed Using the Electroconvulsiometer

• In the ETZ test: The electroconvulsiometer delivers incrementally increasing current to find the minimum current that produces a defined seizure endpoint (e.g., tonic hindlimb extension or clonic seizure) in 50% of animals (CC₅₀ or ET₅₀). After drug treatment, this threshold current is re-measured. A higher threshold after drug indicates anticonvulsant protection.
• In the MES test: A fixed supramaximal current is delivered. The endpoint is whether THLE is present or absent (not the threshold current).
• ETZ is more sensitive; MES is more standardized and widely used for initial screening

SECTION 7: Phases of MES Convulsion

• Immediate, brief generalized flexion of all four limbs and trunk
• The animal curls inward
• Represents initial seizure onset and spread

• The hallmark phase of MES
• All four limbs extend rigidly; hind limbs extend posteriorly at ≥180° to the body axis (in line with the spine or beyond)
• Forelimbs may extend anteriorly
• Tail is rigidly extended
• Animal is fully rigid, like a plank
• Represents maximal seizure spread across the entire brain
• In clinical terms: corresponds to the tonic phase of human Grand Mal seizure
• This is the phase abolished by anticonvulsant drugs - its prevention = anticonvulsant protection

• Rapid, rhythmic, symmetric jerking movements of all four limbs
• Animal bounces repeatedly
• Corresponds to the clonic phase of human tonic-clonic seizure
• Some drugs that do not abolish THLE may still reduce the duration of clonic phase

• The animal lies motionless, unresponsive, with reduced muscle tone
• Represents widespread post-ictal CNS depression following the seizure
• Corresponds to post-ictal confusion/drowsiness in humans

• The animal gradually regains posture, righting reflex, and normal behavior
• Full recovery typically occurs within 5-15 minutes

• It represents the maximal, generalized spread of epileptic discharge - the equivalent of human Grand Mal
• It is all-or-none (present or absent) - easy to score without specialized equipment
• It is the most reliably abolished phase with clinically relevant anticonvulsants
• NINDS defines protection as: "abolition of the hindlimb tonic extensor component"
• Reduction in THLE duration correlates with degree of anticonvulsant potency

SECTION 8: Procedure

• Switch on the electroconvulsiometer; allow 5-minute warm-up
• Set current: 50 mA; frequency: 60 Hz; duration: 0.2 seconds
• Verify ammeter reads zero; check electrode leads are connected securely

• Select healthy albino mice (20-30 g); acclimatize 7 days
• Weigh and number each animal
• Divide into groups: Group 1 (control/vehicle), Group 2 (test drug)

• Administer test drug or vehicle i.p.
• Wait the pre-treatment time (typically 30-60 minutes for i.p. phenytoin at 25-30 mg/kg)

• Apply one drop of 0.9% normal saline (or 0.5% tetracaine HCl for analgesia) to each cornea
• Gently hold the mouse by the scruff (loose skin at back of neck)
• Place corneal electrodes firmly on both corneas simultaneously

• Press the shock/trigger button to deliver the 50 mA, 60 Hz, 0.2-second AC stimulus
• Remove electrodes immediately after the pulse

• Hold the mouse in a consistent horizontal position after the shock
• Observe and time each phase: flexion, THLE (Y/N; duration), clonic, stupor, recovery
• Record: Is THLE present or absent?

• Place the animal in a recovery cage; observe until full recovery
• Do not leave animals unattended until fully mobile

• Tabulate findings; calculate % protection; compare groups statistically

• Control: 0% protection
• Phenytoin (25-30 mg/kg): expected 80-100% protection

SECTION 9: Models Using the Electroconvulsiometer

• Delivers supramaximal current (50 mA/60 Hz/0.2 sec via corneal electrodes in mice)
• Produces a complete tonic-clonic convulsion with THLE in 100% of untreated animals
• Clinically represents: Generalized tonic-clonic (Grand Mal) epilepsy
• Seizure mechanism modeled: Failure to limit seizure spread from a focus - the primary mechanism targeted by phenytoin and carbamazepine (Na⁺ channel block)
• Predicts efficacy of drugs against generalized tonic-clonic and focal (partial) seizures in humans

• A drug that is MES-active but PTZ-inactive (like phenytoin) will be useful for tonic-clonic epilepsy only
• A drug that is PTZ-active but MES-inactive (like ethosuximide) is useful for absence epilepsy only
• A drug active in both models (like valproate, phenobarbitone) may have a broad spectrum of antiepileptic activity
• Using both models together ensures that a new compound's complete anticonvulsant profile is captured and no major class of activity is missed

SECTION 10: Applications of the Electroconvulsiometer

1. Primary anticonvulsant drug screening - first-line tool for identifying new AEDs effective against GTC epilepsy
2. Dose-response studies - determine ED₅₀ for new compounds using probit analysis
3. Comparison of anticonvulsants - compare potency of two AEDs at equivalent doses
4. Seizure threshold determination - ETZ/EST tests to quantify how much a drug raises seizure threshold
5. Drug interaction studies - test whether two AEDs show synergism or antagonism in MES model
6. Mechanism studies - combine with specific receptor antagonists to confirm mechanism (e.g., flumazenil blocks benzodiazepine protection in MES)
7. Neurotoxicity profiling - combine with rota-rod test to calculate Protective Index (PI = TD₅₀/ED₅₀); higher PI = safer drug
8. Evaluation of herbal/natural products - screen plant extracts for anticonvulsant activity
9. Kindling model - repeated subthreshold stimulations progressively lower the seizure threshold, modeling epileptogenesis; used in epilepsy research
10. Brain injury studies - assess seizure susceptibility changes after traumatic brain injury

SECTION 11: Protective Index

• TD₅₀ = Dose producing neurological toxicity (motor impairment) in 50% of animals - measured by the Rota-Rod test (ataxia/incoordination threshold)
• ED₅₀ = Dose producing anticonvulsant protection in 50% of animals in the MES test

• PI > 1: Drug has anticonvulsant activity at doses below those causing toxicity - potentially useful
• PI > 3-5: Good therapeutic index; likely clinically viable
• Higher PI = wider safety margin = better drug

SECTION 12: Anticonvulsant Drug Classification

SECTION 13: Convulsant Agents (Chemical Convulsants)

SECTION 14: Precautions and Ethical Aspects

1. Verify supramaximal current: Confirm all control animals convulse before proceeding; adjust current upward if any control animal fails to show THLE
2. Apply saline to corneas: Before every corneal electrode placement to ensure good conductivity and prevent corneal injury
3. Calibrate the instrument: Verify ammeter reading matches the set current before each session
4. Hold the animal correctly: Grasp mouse by scruff immediately after shock in a horizontal position to observe THLE properly; holding at an angle can simulate or mask THLE (false result)
5. Do not re-shock immediately: Allow full recovery (minimum 10-15 min) before any repeat stimulation; back-to-back shocks can cause spreading depression or cardiac arrhythmia
6. One observer per animal: Have a dedicated observer per animal to accurately time each convulsive phase
7. Maintain consistent parameters: Do not change current/duration/frequency between groups
8. Personnel safety: The electroconvulsiometer can deliver currents harmful to humans; the shock button must only be pressed when the electrodes are on the animal - never when free in air
9. CPCSEA/IAEC approval: Mandatory before conducting the experiment; obtain ethical clearance
10. Emergency humane endpoint: If an animal fails to recover within 5 minutes of a convulsion, apply humane endpoint

1. Narrow spectrum: MES only detects drugs effective against GTC epilepsy; misses drugs for absence, myoclonic, or focal seizures - must combine with PTZ and other models
2. Not a naturalistic model: Electrical stimulation is not how epilepsy actually originates; it bypasses the pathological changes of true chronic epilepsy
3. Does not model epileptogenesis: The MES model tests whether a drug prevents seizure expression - it does not model the progressive development of epilepsy (kindling models are needed for this)
4. Species differences: Seizure threshold and drug response vary between mice and rats, and between strains
5. Does not predict all clinical outcomes: Some drugs effective in MES (like phenytoin) are not effective in all human GTC epilepsy patients; clinical correlation is imperfect
6. Animal welfare concern: Electrical convulsions are a severe stressor; the experiment must minimize animal numbers per 3Rs
7. Anesthesia consideration: Pre-treatment with some drugs (CNS depressants) may affect the seizure threshold independently of specific anticonvulsant mechanisms

SECTION 15: Quick-Fire Questions

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan

• Adams & Victor's Principles of Neurology, 12th Edition - AED mechanisms, classification table
• IJPS Journal - "Instrumental Approaches in Neuropharmacological Screening" - Electroconvulsiometer components and principle
• NINDS/NIH Anticonvulsant Screening Program (panache.ninds.nih.gov) - MES standard parameters
• Melior Discovery MES Model data - Phenytoin dose-response
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed
• SK Kulkarni, Handbook of Experimental Pharmacology

Viva Questions & Answers: Analgesic Activity of Morphine Using Tail Flick Method

For MD Pharmacology Examination

SECTION 1: Aim, Introduction & Definitions

• Nociception: The neural process of encoding and processing noxious stimuli by peripheral nociceptors and their central pathways - it is a purely neurophysiological process
• Pain: Nociception + the conscious, subjective, emotional experience
• Nociception can occur without pain (e.g., under anesthesia) and pain can occur without nociception (e.g., phantom limb pain, psychogenic pain)
• The tail flick test specifically measures nociceptive reflexes, not the subjective pain experience

1. Strong agonists: Morphine, fentanyl, pethidine, methadone, oxycodone, hydromorphone
2. Mild-moderate agonists: Codeine, tramadol, buprenorphine (partial agonist)
3. Mixed agonist-antagonists: Pentazocine, nalbuphine, butorphanol
4. Antagonists: Naloxone, naltrexone

1. NSAIDs: Aspirin, ibuprofen, diclofenac, ketorolac (COX-1/COX-2 inhibitors)
2. Selective COX-2 inhibitors: Celecoxib, etoricoxib
3. Para-aminophenol derivatives: Paracetamol (acetaminophen)
4. Adjuvant analgesics: Amitriptyline, gabapentin, pregabalin, carbamazepine

SECTION 2: The Tail Flick Test - Principle and Rationale

1. A focused radiant heat source (infrared light beam/nichrome wire coil) is applied to the dorsal surface of the rat's tail
2. The heat generates pain signals via Aδ (fast, sharp pain) and C fibers (slow, burning pain) in the tail
3. These signals are transmitted to the dorsal horn of the spinal cord via the spinothalamic tract
4. A spinal reflex arc causes the tail muscles to contract and flick the tail away from the heat source
5. The time from heat application to tail withdrawal = tail flick latency (reaction time)

• Morphine acts on mu-opioid receptors in the spinal cord (dorsal horn), brainstem, and brain
• It inhibits pain signal transmission and suppresses the reflex response
• The tail flick latency is significantly prolonged (or a complete suppression is seen)
• Increased reaction time = analgesic activity

• The tail flick is predominantly a spinal reflex - the response is mediated mainly by spinal cord circuits
• Opioid analgesics, including morphine, act powerfully on mu-opioid receptors in the dorsal horn of the spinal cord (substantia gelatinosa)
• The test is therefore highly sensitive to opioids and has good predictive validity for clinically used opioid analgesics
• The test is not sensitive to NSAIDs (aspirin, paracetamol) at standard doses because NSAIDs primarily block peripheral prostaglandin synthesis and have minimal effect on spinal reflex-mediated thermal nociception
• This makes it a selective model for centrally acting analgesics

SECTION 3: Apparatus and Requirements

1. Radiant heat source: A focused infrared light beam or a heated nichrome wire coil placed in a slot/groove; directs intense heat to a defined spot on the tail
2. Animal holder/restrainer: A cylindrical tube that holds the rat comfortably with its tail protruding through a slot, preventing excessive movement while allowing free tail withdrawal
3. Photocell/sensor: Detects tail movement (withdrawal) and stops the timer automatically in automated versions
4. Digital timer: Records the latency from heat application to tail flick in seconds
5. Cut-off timer: Automatically cuts off heat after a set maximum time (typically 10-15 seconds) to prevent tissue damage
6. Intensity control: Adjusts the heat intensity to produce a baseline reaction time of ~3-5 seconds in untreated animals

• Species: Wistar or Sprague-Dawley albino rats (most common; tail flick is more standardized in rats)
• Weight: 150-200 g
• Mice can also be used (Swiss albino, 20-30 g) but rats give more reliable results due to their larger, more accessible tail
• Animals are acclimatized for at least 7 days; drug-naive; uniform body weight within ±20% of group mean

• S.C. injection gives slower, more sustained absorption than i.p., resulting in a longer duration of peak analgesic effect
• The peak plasma concentration is well-defined (~20-30 min post s.c.)
• S.C. morphine is more predictable and less variable than i.p. in rodents
• Avoids the rapid pharmacokinetic swings seen with i.v. administration
• Ensures animals remain in the peak effect window during the observation period

SECTION 4: Procedure

• Group 1 (Control): s.c. normal saline
• Group 2 (Test): s.c. morphine sulfate 5 mg/kg

• T₁ = baseline reaction time (pre-drug)
• T₂ = reaction time after drug
• Cut-off time = maximum allowed time (e.g., 10 seconds)

SECTION 5: Results and Inference

• Morphine at 5 mg/kg s.c. produces a significant, dose-dependent increase in tail flick latency starting at 20-30 minutes after injection
• Peak effect at 30-45 minutes post s.c. injection
• Tail flick latency may approach or reach the cut-off time (10 sec) at peak - reflecting near-complete antinociception
• The effect gradually wanes over 2-4 hours
• Control (saline) animals show no significant change in reaction time

SECTION 6: Mechanism of Action of Morphine

1. Presynaptic effect - Closes voltage-gated Ca²⁺ channels:
   • At presynaptic nociceptive nerve terminals (first-order neurons in the dorsal horn), morphine activates μ receptors → inhibits adenylyl cyclase → reduces cAMP → reduces Ca²⁺ influx
   • This decreases release of pain neurotransmitters including glutamate, substance P, CGRP, and acetylcholine
   • Net result: Less pain signal transmitted from primary afferents to second-order neurons in the dorsal horn
2. Postsynaptic effect - Opens K⁺ channels:
   • On postsynaptic neurons (second-order neurons in the dorsal horn; also in brain), μ receptor activation opens inwardly rectifying K⁺ channels
   • K⁺ efflux causes hyperpolarization of the postsynaptic membrane
   • The neuron becomes less responsive to incoming excitatory signals
   • Net result: Reduced pain signal propagation up the spinothalamic tract

1. Supraspinal level: Periaqueductal grey (PAG) in the midbrain - activates descending inhibitory pathways to the spinal cord via norepinephrine and serotonin; this is the most important supraspinal site
2. Spinal cord level: Dorsal horn substantia gelatinosa (laminae I and II) - inhibits release of substance P and glutamate from primary afferents; hyperpolarizes second-order neurons
3. Peripheral level: In inflamed tissue, peripheral μ receptors are upregulated; peripheral opioids (e.g., intra-articular morphine) provide local analgesia
4. Brainstem: Locus coeruleus (NE pathways), raphe nuclei (5-HT pathways) - contribute to descending inhibition

SECTION 7: Pharmacological Effects of Morphine

1. Analgesia - most important therapeutic effect; both spinal and supraspinal
2. Euphoria/Sedation - sense of well-being; contributes to dependence potential
3. Respiratory depression - most dangerous effect; decreases sensitivity of brainstem respiratory center to CO₂; occurs at therapeutic doses
4. Antitussive - suppresses cough center in medulla
5. Miosis (pinpoint pupils) - stimulates Edinger-Westphal nucleus; does not develop tolerance; pathognomonic sign in overdose
6. Nausea and vomiting - stimulates chemoreceptor trigger zone (CTZ) in the medulla (area postrema)
7. Decreased body temperature (hypothermia) at high doses

• Histamine release → peripheral vasodilation → hypotension
• Bradycardia (vagal stimulation at high doses)

• Constipation (most consistent side effect; does NOT develop tolerance): decreases peristalsis, increases sphincter tone
• Spasm of biliary/sphincter of Oddi: can worsen biliary colic (use pethidine/meperidine instead)

• Urinary retention (sphincter contraction, decreased detrusor tone)

• Bronchoconstriction (avoid in asthma)
• Urticaria, flushing, pruritus at injection site

SECTION 8: Pharmacokinetics of Morphine

SECTION 9: Adverse Effects and Overdose

• Constipation (most consistent; no tolerance)
• Respiratory depression (most dangerous; CO₂ sensitivity reduced)
• Analgesia + euphoria (therapeutic)
• Miosis (pinpoint pupils - no tolerance; diagnostic in overdose)
• Pruritus (histamine release)
• Dependence and tolerance (physical and psychological)

1. Miosis (pinpoint pupils)
2. Respiratory depression (slow, shallow breathing)
3. Coma / Loss of consciousness

• Dose: 0.4-2 mg IV; repeat every 2-3 minutes as needed (max 10 mg)
• Onset: 1-2 minutes; duration: 30-90 minutes (shorter than morphine → re-narcotization possible)
• Reverses all three features of the opioid triad within minutes
• Also available as intranasal formulation (Narcan nasal spray) for community use

SECTION 10: Comparison of Analgesic Test Models

SECTION 11: Endogenous Opioid System

• Stress activates the hypothalamic-pituitary-adrenal axis and sympathoadrenal system
• This triggers release of β-endorphins from the anterior pituitary (POMC cleavage)
• β-Endorphins activate μ receptors in the PAG and dorsal horn
• Descending inhibitory pathways are activated
• This is also the mechanism behind placebo analgesia and the analgesic effect of exercise (runner's high)

SECTION 12: WHO Analgesic Ladder

SECTION 13: Precautions and Limitations

1. Set the cut-off time (10-15 sec) and strictly enforce it - prolonged heat application causes tissue burns/necrosis of the tail
2. Ensure the same tail position on the heat source for every reading; inconsistent positioning gives variable results
3. Allow animals to acclimatize in the restrainer before testing - initial stress can elevate baseline latency
4. Take 2-3 baseline readings per animal and average them to reduce variability
5. Test at the same time of day - pain sensitivity shows circadian variation
6. Consistent environmental conditions - quiet, stable temperature and lighting
7. Use animals of uniform sex, weight, and age - body weight affects drug distribution; sex hormones affect pain sensitivity
8. Follow CPCSEA/IAEC guidelines for ethical animal use
9. Do not re-test the same animal until full recovery (>30 min between readings in chronic studies)
10. Note: Morphine is a Schedule H1 drug in India and a controlled substance under the Narcotic Drugs and Psychotropic Substances Act (NDPS Act); requisition from the institution and proper record-keeping are mandatory

1. Purely spinal reflex: Does not assess supraspinal or cortical components of pain processing (hot plate test is better for this)
2. Thermal nociception only: Does not model inflammatory pain (writhing test), neuropathic pain, or visceral pain
3. Not sensitive to NSAIDs: A drug that relieves clinical pain via COX inhibition will not be detected in this model
4. Tolerance develops rapidly: Repeated morphine administration markedly shortens the analgesic response - must account for this in chronic studies
5. Animal-to-animal variability: Baseline tail flick latency varies considerably even within the same strain
6. Temperature sensitivity: Ambient temperature affects baseline readings; must be controlled

SECTION 14: Quick-Fire Questions

1. Close voltage-gated Ca²⁺ channels (presynaptic - reduces substance P/glutamate release)
2. Open K⁺ channels (postsynaptic - hyperpolarizes neurons) (Katzung, 16th Edition)

• Hot plate test (Woolfe & MacDonald, 1944) - supraspinal thermal nociception
• Writhing test / Acetic acid test - visceral/chemical nociception; detects both opioids and NSAIDs
• Also: Randall-Selitto test (paw pressure), formalin test, Von Frey filaments (mechanical allodynia), CCI model (neuropathic pain)

• Katzung's Basic and Clinical Pharmacology, 16th Edition - Opioid receptor types, cellular mechanism, receptor subtypes
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Morphine clinical pharmacology, WHO ladder
• D'Amour FE, Smith DL (1941) - Original description of the tail flick test
• RJPT Simlab - Tail flick procedure and principle
• PMC (Quercus infectoria study) - Morphine MPA data in tail flick model
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed

Viva Questions & Answers: TAIL FLICK METHOD AND APPARATUS

For MD Pharmacology Examination

SECTION 1: Introduction & History

• It is the gold standard for screening centrally acting (opioid) analgesics in preclinical pharmacology
• It is simple, reproducible, quantitative, and non-invasive (compared to chemical pain models)
• It has high predictive validity - drugs effective in the tail flick test (morphine, fentanyl, codeine) consistently prove clinically effective analgesics
• Endorsed by regulatory agencies (OECD) as a standard preclinical analgesic model
• It provides a clean, spinal reflex-based endpoint minimally confounded by motor or emotional factors

SECTION 2: Principle

1. Stimulus: A focused, intense heat source (radiant infrared beam or hot water) is applied to the dorsal surface of the tail
2. Nociceptor activation: Heat activates Aδ (type II AMH - heat-responsive) and C-fiber (polymodal) nociceptors in the skin of the tail, generating pain signals
3. Spinal reflex arc: These pain signals travel via Aδ and C fibers (primary afferents) → enter the dorsal horn of the spinal cord (laminae I, II, V) → activate spinal interneurons and motor neurons → trigger tail withdrawal reflex
4. The time from heat application to tail flick = Tail Flick Latency (TFL)
5. Drug effect: Opioid analgesics act on μ-opioid receptors in the dorsal horn and brainstem → suppress nociceptive signal transmission → animal takes longer to withdraw the tail (increased latency) or does not flick at all (complete antinociception up to cut-off time)

SECTION 3: The Apparatus - Construction and Components

• Analgesiometer (most common name in Indian pharmacology labs)
• Tail Flick Apparatus
• Tail Flick Analgesiometer
• Eddy's Analgesiometer (refers to the thermal model, though strictly refers to hot plate)

1. Radiant heat (light beam) type - standard; uses a focused infrared light beam
2. Hot water immersion type - tail dipped in hot water bath (tail immersion method)

A. Heat Generation System

1. Radiant heat source / infrared lamp: A focused infrared (IR) light or a nichrome wire heating element placed in a parabolic reflector that concentrates heat onto a small defined spot (typically ~1 mm diameter) on the tail. The IR lamp is the most common.
2. Set current control / rheostat / intensity control knob: Adjusts the electrical current passing through the heating element, controlling the intensity (temperature) of the focused heat beam. Calibrated to produce a baseline tail flick latency of 3-5 seconds in normal untreated animals.
3. Main power supply (ON/OFF switch): Powers the heating element and timer circuit.

B. Animal Holder

1. Restraining tube / animal holder: A cylindrical transparent acrylic or metal tube that loosely holds the rat or mouse in a comfortable, horizontal position with its tail protruding through a slot at one end. The animal is restrained enough to prevent excessive movement but not so tightly as to cause distress or positional pain. The tail rests flat on the heat source groove.

C. Timer System

1. Automatic timer / counter: Starts the moment heat is applied and stops automatically when the tail is flicked. Displays the latency in seconds (to 0.1 second precision).
2. Photodetector / infrared sensor: Detects the tail movement (withdrawal) and automatically stops the timer in automated versions; eliminates observer bias.
3. Cut-off timer / automatic switch-off: Automatically cuts off the heat after a preset maximum time (10-15 seconds) if the animal does not flick its tail, preventing tissue burns and corneal damage.

D. Display

1. Digital display panel: Shows the recorded latency time in seconds.
2. Indicator meter: Some models display the current/voltage applied to the heating element, confirming calibration.
3. Data output port (modern models): USB or serial port for data upload to PC with pharmacology software.

SECTION 4: Types of Tail Flick Tests

• Focused IR beam on dorsal tail surface
• Most widely used standard method
• Highly reproducible

• Distal 5 cm of tail immersed in water at 50-55°C
• Endpoint: active tail withdrawal from water
• Simple; no specialized apparatus required
• Both heat and water immersion activate Aδ and C fiber nociceptors

• Tail immersed in cold water (2-4°C) instead of hot water
• Endpoint: tail withdrawal latency from cold water
• Key advantage: distinguishes pure μ opioid agonists from mixed agonist-antagonists (like pentazocine) - pentazocine is ineffective in the cold water tail flick test but effective in the hot water model

• Similar principle but heat applied to the plantar surface of the hind paw (not the tail)
• Measures paw withdrawal latency
• Particularly useful for studying inflammatory hyperalgesia after CFA (complete Freund's adjuvant) injection
• Supraspinal processing more involved than classic tail flick

SECTION 5: Neural Basis - Pain Pathway

• Primary afferent Aδ fibers synapse in laminae I and V of the dorsal horn
• C fibers synapse in laminae I and II (substantia gelatinosa)
• Neurotransmitters released: Glutamate (fast, AMPA/NMDA), Substance P, CGRP
• Second-order neurons in the dorsal horn are activated

• The signal activates interneurons within the spinal cord (WITHOUT going to the brain for the basic reflex)
• Motor neurons in the ventral horn are activated → contract tail musculature → tail flick
• This is a spinally mediated reflex - can occur even after spinal cord transection above the tail segment

• Second-order neurons cross the midline via the anterior white commissure and ascend in the lateral spinothalamic tract (STT)
• Project to the thalamus (VPL nucleus) → somatosensory cortex (conscious localization)
• Also project to hypothalamus, PAG, amygdala (emotional/affective component)

• The Periaqueductal Grey (PAG) in the midbrain → rostral ventromedial medulla (RVM) → dorsal horn
• This pathway releases serotonin, norepinephrine, and enkephalins that inhibit dorsal horn neurons
• Morphine activates μ receptors in the PAG, activating this descending inhibitory pathway

• Inhibitory interneurons (SG neurons) in the dorsal horn act as a "gate" that can open or close pain transmission to higher brain centers
• Large-diameter, fast-conducting Aβ fibers (touch, pressure) activate SG neurons → CLOSE the gate → suppress pain signals from C fibers
• Small-diameter Aδ and C fibers (pain) inhibit SG neurons → OPEN the gate → allow pain to pass
• Descending controls from the brain can also modulate the gate

• The tail flick test bypasses supraspinal cognitive gates (it's a spinal reflex)
• Opioids close the gate at the spinal cord level by directly inhibiting dorsal horn nociceptive neurons
• Non-opioid analgesics that work via peripheral prostaglandin inhibition do not significantly close this spinal gate - explaining why NSAIDs have minimal effect in the tail flick test

SECTION 6: Procedure

• Switch on the analgesiometer; allow 5-minute warm-up
• Adjust current intensity using the rheostat to produce a baseline tail flick latency of 3-5 seconds in 2-3 untreated animals
• Set the cut-off time at 10-15 seconds
• Verify the automatic shut-off works correctly

• Select Wistar/Sprague-Dawley rats (150-200 g) or albino mice (20-30 g)
• Acclimatize 7 days; fast for 12 hours if oral drug administration is used
• Weigh and number each animal
• Divide into groups: Control (saline) and Test (drug)

• Place each animal in the restrainer for 5-10 minutes before testing to reduce novelty stress-induced analgesia

• Position the tail on the heat source so the mid-dorsal portion (3-5 cm from base) rests on the focal point of the heat beam
• Apply heat; start timer; observe tail flick; note time
• Repeat 2-3 times at 5-minute intervals; take average as T₁ (baseline)
• Exclude animals with baseline T₁ <2 sec (too sensitive) or >6 sec (hyposensitive)

• Administer morphine sulfate (5 mg/kg s.c.) or vehicle s.c./i.p.

• Test at 30, 60, 90, and 120 minutes post-injection to capture the time-effect curve
• Record T₂ at each time point

• If the animal does not flick within the cut-off time, record T₂ = cut-off time and immediately remove the tail from heat source

• Calculate %MPA and create time-effect curve

• T₁ = baseline (pre-drug) latency
• T₂ = post-drug latency
• Cut-off = 10 seconds

• Two groups: Student's unpaired t-test
• Multiple groups or time points: Two-way ANOVA (time × treatment) with Bonferroni or Tukey's post-hoc test
• Dose-response: Calculated ED₅₀ by probit analysis

SECTION 7: Results and Interpretation

• Morphine (5 mg/kg s.c.) produces a significant, dose-dependent increase in TFL starting at 20-30 min
• Peak effect: 30-45 minutes post-injection; TFL may reach cut-off time (full antinociception)
• Duration: 2-4 hours in rats
• %MPA at peak: typically 60-90% at 5-10 mg/kg
• Control (saline) animals: no significant change in TFL across time points

• Opioid analgesics (morphine, codeine, fentanyl): Significantly increase TFL - the tail flick test is highly sensitive to these
• NSAIDs (aspirin, ibuprofen, diclofenac): Little or no effect on TFL at standard doses - the test has very low sensitivity for these peripherally acting drugs
• Paracetamol: Slight increase at high doses (may have some central component)
• This selective sensitivity makes the tail flick test specifically useful for opioid screening

SECTION 8: Applications of the Tail Flick Method

1. Primary screening of opioid analgesics - most important application; detect new opioid compounds
2. Potency ranking of opioid drugs - compare analgesic potency via ED₅₀ ratios
3. Dose-response studies - establish ED₅₀ and compare with TD₅₀ (via rota-rod) to calculate Protective Index
4. Evaluation of analgesic tolerance - measure progressive decrease in TFL prolongation with repeated morphine dosing
5. Opioid antagonist studies - demonstrate complete reversal of morphine-induced TFL increase by naloxone (confirms μ receptor mechanism)
6. Characterization of new natural products / plant extracts for analgesic activity
7. Study of descending pain inhibition - PAG stimulation or opioid microinjection studies
8. Differentiating opioid receptor subtypes - using selective agonists and antagonists for μ, κ, δ receptors; cold water variant distinguishes agonists from mixed agonist-antagonists
9. Study of drug interactions - synergism between opioids and co-analgesics (gabapentin, ketamine)
10. Stress-induced analgesia research - measure the antinociceptive effect of stress, exercise, or placebo
11. Circadian rhythm studies - measure diurnal variation in pain sensitivity
12. Disease models - assess hyperalgesia in spinal cord injury, Parkinson's disease, or diabetic neuropathy models

SECTION 9: Comparison with Other Analgesic Test Models

• Tail flick: The tail withdrawal reflex is a polysynaptic spinal reflex - it can occur even in spinally transected animals (spinal cord cut above the tail segment). No supraspinal processing is required for the basic reflex.
• Hot plate: The endpoints (paw licking, jumping) require supraspinal motor planning and emotional processing - they are abolished by spinal transection above the cervical level. The animal must "decide" to lick its paw or jump, which requires cortical and limbic involvement.
• Therefore, a drug may be effective in the tail flick (spinal opioid action) but not hot plate (if supraspinal systems are not activated) - and vice versa
• Morphine is effective in both tests; spinally selective opioids may show only tail flick activity

SECTION 10: Calibration

1. Switch on the apparatus; allow 5-10 minutes warm-up for the IR lamp to stabilize
2. Place an untreated, naive animal in the restrainer
3. Apply heat at the initial intensity setting and record the TFL
4. Adjust the rheostat (current intensity) up or down until the baseline TFL is consistently 3-5 seconds in at least 3 consecutive naive animals
5. Verify the cut-off mechanism works: set cut-off to 10 seconds, apply heat to a stationary object or restrained tail, confirm the heat auto-shuts off at exactly 10 seconds
6. Once calibrated, do not change the intensity setting for the remainder of the experiment
7. Record the calibration current setting for reproducibility in future experiments

SECTION 11: Precautions and Limitations

1. Strictly enforce the cut-off time (10-15 sec): Never allow the heat to continue beyond the cut-off - tissue necrosis/burns occur within seconds at high intensity
2. Same tail position for every reading: Always test the same region of the tail (dorsal surface, 3-5 cm from base); inconsistent positioning changes the local skin temperature and gives variable results
3. Painting the tail black (optional, research labs): The dark pigment absorbs IR radiation more efficiently, giving more consistent heat absorption; important for animals with lightly pigmented tails
4. Calibrate before every session: Lamp intensity drifts over time; always re-calibrate to 3-5 sec baseline
5. Allow at least 5-minute interval between repeated measurements on the same animal to allow tail skin temperature to normalize
6. Acclimatize animals to the restrainer before testing to minimize stress-induced analgesia
7. Consistent environmental conditions: Room temperature, lighting, and noise must be stable - all affect pain sensitivity
8. Exclude extreme responders: Animals with baseline TFL <2 sec (hyperalgesic) or >6 sec (hypoalgesic) should be excluded
9. Test at the same time of day: Pain sensitivity shows significant circadian variation (higher in the dark/active phase in nocturnal rodents)
10. CPCSEA/IAEC guidelines: Follow all ethical requirements; minimize number of animals used (3Rs principle)
11. Opioid handling: Morphine is a controlled substance (Schedule H1, NDPS Act in India); maintain proper records and use with authorized prescription

1. Spinal reflex only: Does not assess supraspinal components of pain (hot plate test needed for this)
2. Thermal stimulus only: Cannot model inflammatory pain (writhing test), neuropathic pain, or chronic persistent pain
3. Not sensitive to NSAIDs: Limits it to detecting centrally acting analgesics; misses drugs that relieve clinical pain by peripheral COX inhibition
4. Variability of skin temperature: Ambient temperature affects skin temperature of the tail, altering baseline latency - must be controlled
5. Tolerance develops rapidly: Repeated morphine dosing produces tolerance; chronic pain studies require tolerance protocols
6. Stressor confound: The restraining tube itself is a mild stressor that activates descending inhibitory pathways, artificially increasing baseline TFL
7. Motor impairment confound: A drug causing muscle relaxation or ataxia (e.g., high-dose diazepam) may fail to flick the tail due to motor impairment rather than true analgesia - this is a false positive
8. Translational limitations: The exact tail flick reflex does not have a direct human analog; pain in humans involves complex cortical processing not captured by this spinal reflex

SECTION 12: Quick-Fire Questions

• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Edition (2011)
• SK Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan

• D'Amour FE, Smith DL (1941) - Original tail flick description
• Ganong's Review of Medical Physiology, 26th Edition - PAG descending pain inhibition, pain pathways
• Barash, Cullen & Stoelting's Clinical Anesthesia, 9th Edition - Opioid analgesic mechanisms at PAG and dorsal horn
• Melior Discovery - Morphine dose-response in rat tail flick
• Pizziketti RJ et al. (1985) - Cold water tail flick test
• RJPT SimLab; Maze Engineers (ConductScience) - Apparatus and procedure details
• MN Ghosh, Fundamentals of Experimental Pharmacology, 5th Ed

Viva Questions & Answers: Analgesic Activity of Diclofenac Using Eddy's Hot Plate Method

For MD Pharmacology Examination

SECTION 1: Aim, Introduction & Rationale

1. It has some central COX-inhibitory activity - crosses the blood-brain barrier at higher doses
2. It reduces peripheral sensitization of nociceptors by prostaglandins, reducing afferent input to the spinal cord and brain
3. At the experimental doses used (10-20 mg/kg i.p. in mice), a significant increase in reaction time is demonstrable
4. The experiment teaches comparative pharmacology: diclofenac shows less potent hot plate analgesia than morphine - illustrating the difference between peripheral and central analgesics

• Is a standard preclinical model of thermal nociception with both spinal and supraspinal components
• Has good predictive validity for clinically effective analgesics
• Allows quantitative measurement of analgesic potency (reaction time, %MPA, ED₅₀)
• Is used to compare analgesic drugs, establish dose-response relationships, and screen new compounds for analgesic activity

SECTION 2: The Apparatus - Eddy's Hot Plate

A. Heating Platform

1. Heated metal plate (hot plate): A precisely thermostatted metal (aluminum or copper) plate, typically 15-20 cm diameter, heated by an electric heating element underneath
2. Temperature control thermostat: Maintains the plate at a constant, precise temperature; standard temperature for mice: 52-56°C (most common: 55°C); must be accurate to ±0.5°C
3. Temperature display/thermometer: Digital thermometer showing the actual plate surface temperature; allows verification before each experiment

B. Animal Enclosure

1. Transparent cylindrical chamber (glass or acrylic cylinder): Placed on the hot plate to confine the mouse on the heated surface; prevents escape while allowing full observation of behavior; typically 15 cm diameter × 20 cm height for mice
2. Open top: Allows the animal to jump out (endpoint) without physical barriers preventing the natural response

C. Timing System

1. Automatic timer/stopwatch: Starts when the animal is placed on the plate; stops automatically when a pain response is detected (in automated systems) or manually stopped by the observer
2. Photodetector (in automated models): Detects paw licking or jumping movements and auto-stops the timer
3. Cut-off timer (automatic switch-off): Automatically removes the animal or sounds an alarm at a preset cut-off time (30 seconds for mice) to prevent paw burns and tissue damage

D. Control Panel

1. Power switch and indicator
2. Rheostat/temperature set dial: Sets the desired plate temperature
3. Digital display: Shows plate temperature and recorded latency time

• Below 52°C: Insufficient thermal stimulus; mice rarely respond - too low to activate heat-sensitive TRPV1 and Aδ nociceptors consistently
• At 55°C: Produces a clear, reproducible baseline response (licking, jumping) in 100% of normal mice within 5-15 seconds without rapid tissue damage
• Above 56°C: Animals respond too quickly (< 2 seconds), reducing the dynamic range to detect drug-induced increases; risk of burns increases sharply
• 55°C is the international standard for most mouse hot plate protocols (NINDS, Melior Discovery)

1. Hind paw licking - the mouse lifts and licks the hind paw to relieve heat pain; the most commonly used primary endpoint
2. Hind paw shaking / stamping - rapid shaking of the hind paw on the hot surface
3. Jumping - the mouse jumps off the hot surface or tries to escape; represents a supraspinally integrated avoidance behavior (requires motivated motor response)
4. Flinching

SECTION 3: Principle

1. When a mouse is placed on the hot plate (55°C), the heat activates Aδ and C fiber nociceptors in the paw skin
2. Pain signals travel via Aδ/C fibers → dorsal horn of the spinal cord → spinothalamic tract → thalamus → somatosensory cortex + limbic system
3. The animal consciously perceives the thermal pain and executes a motivated motor response - paw licking, jumping - which requires supraspinal (cortical + limbic) processing beyond just a spinal reflex
4. The latency to this pain response (reaction time, RT) is the endpoint
5. An analgesic drug:
   • Raises the pain threshold
   • Reduces nociceptive signal transmission
   • Impairs conscious pain perception
   • Results in a prolonged reaction time (longer time before paw licking/jumping)
6. Increased reaction time = analgesic activity

SECTION 4: Animals and Drug

• Species: Albino mice (Swiss albino or CF-1)
• Weight: 20-30 g
• Mice are preferred over rats in the hot plate test because:
  • They show cleaner, more distinct endpoint behaviors (paw lick, jump)
  • More economical (smaller drug doses needed)
  • Easier to handle and confine on the plate
  • Validated across thousands of published studies
• Acclimatized for 7 days; drug-naive; uniform sex and weight

• I.P. injection provides faster and more reliable absorption than oral dosing in mice
• Avoids variable first-pass metabolism via oral route
• Reaches therapeutic plasma levels quickly (10-20 min)
• Standard route for acute pharmacological testing in rodents
• Diclofenac is also available as injection formulation (diclofenac sodium 75 mg/3mL) clinically

SECTION 5: Procedure

• Switch on Eddy's hot plate; allow temperature to stabilize at 55°C (verify with digital thermometer)
• Set the cut-off time at 30 seconds (activate automatic shut-off)

• Weigh and number all mice
• Acclimatize in the testing room for 1 hour

• Place each mouse individually on the hot plate (55°C)
• Start the timer
• Observe for paw licking or jumping
• Record the time to first response as T₁ (baseline reaction time)
• Remove the animal as soon as it responds or at 30 seconds (cut-off)
• Repeat 2-3 times at 5-minute intervals; take the average as T₁
• Exclude animals with baseline T₁ <5 sec (hyperalgesic) or >20 sec (hyposensitive/hypoalgesic; ~spontaneous variation)

• Group 1 (Control): Saline i.p.
• Group 2 (Standard): Morphine 5 mg/kg s.c.
• Group 3 (Test): Diclofenac 10-20 mg/kg i.p.

• Re-test each animal on the hot plate at 30, 60, 90, and 120 minutes after drug administration
• Record T₂ at each time point
• Enforce cut-off: if no response within 30 seconds, record T₂ = 30 and remove immediately

SECTION 6: Results and Expected Outcome

SECTION 7: Mechanism of Action of Diclofenac

• COX-2 in vascular endothelium → produces PGI₂ (prostacyclin) → vasodilation + anti-platelet
• COX-1 in platelets → produces TXA₂ (thromboxane A₂) → vasoconstriction + pro-platelet

• PGI₂ production ↓ (from endothelium)
• TXA₂ production unchanged (platelets have only COX-1)
• Net result: Prothrombotic state → increased risk of myocardial infarction, stroke, thrombosis
• This led to the withdrawal of rofecoxib (Vioxx) from the market in 2004

SECTION 8: Pharmacology of Diclofenac

• Inhibits thromboxane-prostanoid receptor activation
• Inhibits lipoxygenase pathway (reduces leukotriene synthesis)
• Inhibits arachidonic acid release from membranes
• May activate the nitric oxide-cGMP pathway (additional analgesic contribution)

1. Rheumatoid arthritis and osteoarthritis - first-line NSAID
2. Ankylosing spondylitis
3. Acute gout - rapid anti-inflammatory
4. Dysmenorrhea - primary and secondary
5. Musculoskeletal pain - sprains, strains, soft tissue injuries (topical gel)
6. Post-operative pain (i.m./i.v. formulation)
7. Dental pain
8. Migraine (diclofenac potassium - faster acting)
9. Renal colic (acute pain management)
10. Fever (antipyretic)

• Nausea, dyspepsia, abdominal pain (most common)
• Peptic ulceration - gastric and duodenal ulcers
• GI bleeding and perforation (serious)
• Prevention: Use with PPI (omeprazole) or misoprostol; prefer enteric-coated or selective COX-2 inhibitors in high-risk patients

• Increased risk of MI, stroke, heart failure (class effect of all NSAIDs, including diclofenac)
• Diclofenac has higher CV risk than other non-selective NSAIDs (similar to COX-2 selective agents) - shown in PRECISION trial 2016
• Not recommended in patients with established CV disease

• Reduced renal prostaglandin → afferent arteriolar constriction → reduced GFR
• Acute kidney injury, fluid retention, edema, hyperkalemia
• Particularly dangerous in hypovolemia, heart failure, or pre-existing renal disease

• Diclofenac is associated with more hepatotoxicity than most other NSAIDs - rare but serious idiosyncratic hepatocellular damage; LFT monitoring recommended in long-term use

• Skin reactions (rash, urticaria)
• Platelet dysfunction (reduced TXA₂ - less than aspirin; reversible on stopping)
• Avoid in pregnancy: Risk of premature closure of ductus arteriosus (PGE₂-dependent); oligohydramnios; Category C/D
• Analgesic nephropathy with chronic overuse

SECTION 9: Comparison - Diclofenac vs. Morphine in Hot Plate Test

• The hot plate test, particularly the jumping endpoint, is primarily a supraspinal response requiring cortical and limbic pain processing
• Morphine acts directly on central μ opioid receptors in the PAG, thalamus, and dorsal horn - powerfully suppressing central pain processing
• Diclofenac acts mainly peripherally by reducing prostaglandin-mediated nociceptor sensitization. While it also has some central effect (crosses BBB at therapeutic doses), it does not directly modulate the supraspinal circuits involved in the hot plate jumping response
• Therefore, morphine consistently produces a greater and more reliable increase in hot plate latency than diclofenac at standard doses

SECTION 10: COX Inhibitor Classification

1. Salicylates: Aspirin (acetylsalicylic acid), sodium salicylate
2. Acetic acid derivatives: Diclofenac, indomethacin, ketorolac, sulindac, etodolac
3. Propionic acid derivatives: Ibuprofen, naproxen, ketoprofen, flurbiprofen
4. Enolic acid derivatives (Oxicams): Piroxicam, meloxicam, tenoxicam
5. Anthranilic acid derivatives (Fenamates): Mefenamic acid, meclofenamic acid
6. Selective COX-2 inhibitors (Coxibs): Celecoxib, etoricoxib, parecoxib, valdecoxib (withdrawn), rofecoxib (withdrawn)
7. Others: Nimesulide, nabumetone

• Non-selective (COX-1 + COX-2): Aspirin, ibuprofen, diclofenac, indomethacin
• Preferentially COX-2 selective: Meloxicam, nimesulide, etodolac
• Highly selective COX-2: Celecoxib, etoricoxib, parecoxib

• Strong agonists: Morphine, fentanyl, pethidine, oxycodone, methadone
• Mild-moderate agonists: Codeine, tramadol
• Partial agonists: Buprenorphine
• Mixed agonist-antagonists: Pentazocine, nalbuphine, butorphanol
• Antagonists: Naloxone, naltrexone

1. NSAIDs (COX inhibitors) - Aspirin, diclofenac, ibuprofen, ketorolac
2. Selective COX-2 inhibitors - Celecoxib, etoricoxib
3. Para-aminophenol - Paracetamol (acetaminophen)
4. Adjuvants - Gabapentin, pregabalin, amitriptyline, carbamazepine

SECTION 11: Comparison of Analgesic Test Models

• The jumping response in the hot plate test requires cortical decision-making, emotional processing (avoidance motivation), and complex motor planning - these are supraspinal functions
• The paw licking response also involves descending facilitation from the brain
• The tail flick is a pure spinal withdrawal reflex that persists in spinally transected animals - no supraspinal processing needed
• Therefore, a drug may suppress the tail flick (spinal opioid action) without affecting the hot plate (if it doesn't suppress supraspinal processing)

SECTION 12: Precautions and Limitations

1. Temperature must be stable at 55 ± 0.5°C - verify before every animal; even 1-2°C variation significantly changes baseline latency
2. Strictly enforce 30-second cut-off - remove mouse immediately; burned paws can permanently impair behavior and cause ongoing pain that confounds subsequent measurements
3. Use the same endpoint definition throughout (e.g., first hind paw lick - not forepaw) for consistency
4. Allow minimum 5-minute rest between repeated measurements on the same animal
5. Test at the same time of day - pain sensitivity shows circadian variation
6. Quiet, temperature-controlled room - external stressors produce endogenous analgesia (stress-induced analgesia) and falsely elevate baseline
7. Clean the plate surface between animals - urine odors from previous animals may alter behavior
8. Exclude extreme responders - animals with T₁ <5 sec or >20 sec should be excluded
9. Use the same observer throughout the experiment - inter-observer variability in detecting paw lick vs. flinch is significant
10. CPCSEA/IAEC approval and 3Rs principle must be followed

1. Motor impairment confound: Sedatives, muscle relaxants, or anesthetics impair jumping without true analgesia - giving false positives; must distinguish true analgesia from motor impairment (use rota-rod test as control)
2. Tolerance develops with repeated testing (learning) or repeated opioid administration
3. Less sensitive to NSAIDs than inflammatory pain models (writhing test) - limits its utility for non-opioid analgesic screening
4. Burning risk if cut-off not strictly enforced - burns cause persistent pain and behavioral changes
5. Variable endpoints - paw lick vs. jump involve different neural circuits; lumping them reduces precision
6. Translational limitations - jumping in response to heat is not directly analogous to any human pain experience
7. Social stress: Mice are stressed by isolation in the test apparatus, activating stress-induced analgesia